Fiscal year ended August 2026 Financial Results Presentation
Filed with TSE · · 27 pages · English
Summary by 6ix AI
The report highlights a decrease in research and development expenses, alongside a net loss for the year, reflecting ongoing investments in clinical trials and product development. Additionally, the company secured financing through stock acquisition rights to support its operational activities and clinical trial preparations. The presentation outlines key priorities for the upcoming fiscal year, focusing on advancing its drug pipeline and enhancing investor engagement.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Chordia Therapeutics Inc. on 6ix
In the deck
Earlier from Chordia Therapeutics
- Non-consolidated Financial Results for the Fiscal Year Ended August 31, 2026 [Japanese GAAP]
- Announcement Regarding AMED Grant Award for rogocekib (CTX-712)
- Announcement Regarding Completion of Patient Enrollment in the Initial Expansion Cohort of rogocekib
- Announcement of Orphan Drug Designation in Japan for rogocekib for Relapsed or Refractory AML
- Announcement Regarding the Review Status of Orphan Drug Designation for Rogocekib, a CLK Inhibitor
Follow Chordia Therapeutics into a list and get an email when it puts out news.
Follow Chordia Therapeutics